Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Survey of Prostate Cancer in Accra, Ghana
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), May 2008
Sponsors and Collaborators: National Cancer Institute (NCI)
National Center on Minority Health and Health Disparities (NCMHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00339534
  Purpose

This study, conducted at Korle-Bu Hospital in Accra, Ghana, will help elucidate the roles of lifestyle and genetic factors in prostate cancer risk. There is a strong variation in risk of prostate cancer throughout the world. The rates of the disease among African Americans are some of the world's highest. In the United States, the incidence of prostate cancer is 70 percent higher in African Americans than in white Americans and the death rate in African Americans is almost double that of white Americans. The reasons for this excessive risk are unknown, but both genetic and lifestyle factors have been suggested.

Because Africans and African Americans share similar genetic ancestry but have vastly different lifestyles, a better understanding of the rates and risk factor profiles for prostate cancer among Africans will provide important clues to what causes the disease. This study will try to assess the incidence of prostate cancer in the West African nation of Ghana. The study has two components:

  • Clinical survey - The methods of diagnosis at Korle-Bu will be evaluated and the incidence of prostate cancer over a 5-year period will be estimated.
  • Screening and detection survey - A survey of 1,000 men between 50 and 74 years of age will estimate the prevalence of both asymptomatic and undiagnosed symptomatic prostate cancer in the Accra population.

The clinical survey will use data from the cancer logbook and medical records at Korle-Bu Hospital and the Ghanaian National Census to derive an estimate of prostate cancer incidence within Accra. The estimate will be low, since it will be based only on men diagnosed or treated at Korle-Bu and will not include men with asymptomatic disease, men diagnosed elsewhere, or men without access to medical care. The screening and detection survey will assess the presence of asymptomatic and unrecognized symptomatic prostate cancer using PSA testing and digital rectal examination in a random sample of 1,000 men in the general population of Accra. This will provide a high estimate of disease prevalence. The two estimates will provide an approximation of the true incidence rate of the disease in Accra.

Comparison of these data with similar data from community surveys of African Americans will provide insight into reasons for the excess risk of prostate cancer in African Americans.


Condition
Prostate Cancer

MedlinePlus related topics: Cancer Prostate Cancer
U.S. FDA Resources
Study Type: Observational
Official Title: Survey of Prostate Cancer in Accra, Ghana

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1600
Study Start Date: June 2002
Detailed Description:

The key aim of this study is to assess the burden of prostate cancer in Ghana to evaluate how the impact of prostate cancer among West Africans compares to that among African-Americans, whose reported incidence rates are among the highest in the world. West Africans and African-Americans share genetic ancestry but have very different lifestyle and environmental exposures. The study aim will be achieved by deriving lower and upper bounds on the true incidence of prostate cancer in the capital city of Accra.

  Eligibility

Ages Eligible for Study:   50 Years to 74 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

The 1,000 Accra residents selected for screening will include 300 men 50-59, 400 men 60-69, and 300 men 70-74 years of age.

EXCLUSION CRITERIA:

Men who do not meet the age requirements will be excluded from the study.

In addition, men who have a history of prostate cancer for which they have received treatment will also be excluded (men with untreated prostate cancer will be included).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00339534

Contacts
Contact: Ann Hsing, Ph.D. (301) 435-3980 hsinga@exchange.nih.gov

Locations
United States, District of Columbia
GW University Medical Center GW Hospital Center Recruiting
Washington, District of Columbia, United States, 20037
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
United States, North Carolina
Research Triangle Institute/Office of Research Protection and Ethics Recruiting
Research Triangle Park, North Carolina, United States, 27709
Ghana
University of Ghana Recruiting
Legon, Accra, Ghana
Korle-Bu Teaching Hospital Recruiting
Accra, Ghana
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 999902240, 02-C-N240
Study First Received: June 19, 2006
Last Updated: July 18, 2008
ClinicalTrials.gov Identifier: NCT00339534  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Epidemiology
Africa
Urology
Cancer Incidence
Black-White Health Disparities
Cancer
Prostate Cancer

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009